An interventional study of Active peroneal transcutaneous neuromodulation (URIS I, Stimvia) and Sham peroneal transcutaneous neuromodulation (URIS I, Stimvia) in Overactive Bladder and Daytime Urinary Incontinence, sponsored by General University Hospital, Prague. Recruiting at 1 site in Czechia. Open to participants aged 7 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by General University Hospital, Prague · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Urinary Bladder, Overactive with a site in Czechia — 3 open to participants now, 3 under way, none of them phase 3. Urinary Bladder, Overactive · Czechia.
Among the 39 studies in Urinary Bladder, Overactive with a site in Czechia, this one is the 32nd largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 with no phase, and was the 39th registered.
859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.
Browse Urinary Bladder, Overactive studies →3 of the 39 studies in Urinary Bladder, Overactive with a site in Czechia are open now. Recruiting first, the newest first:
University Hospital Ostrava · Sites in Czechia
Ages 18+ · Women only
University Hospital Ostrava · Sites in Czechia
Ages 18+
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 74 Urinary Bladder, Overactive studies recruiting now, 44 (59%) set no upper age limit and 16 (22%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 7 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 47 is below the median of 70 across 650 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 596 across the 34 interventional studies, 300 across the 5 observational. Of the 36 that completed or were terminated, 21 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 39 have an industry lead sponsor. The 10 most frequent:
General University Hospital, Prague is the lead sponsor of 38 studies on the registry; 24 are open to participants now.
General University Hospital, Prague has 1 study filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
1 of the studies in Urinary Bladder, Overactive with a site in Czechia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06921746University Hospital OstravaChanges in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Urinary Bladder, Overactive with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, randomized, sham-controlled clinical investigation evaluates the efficacy and safety of peroneal transcutaneous electrical neuromodulation (URIS I system) in children aged 7-12 years with wet overactive bladder and daytime urinary incontinence who did not respond or responded insufficiently to standard urotherapy. Participants are randomized 1:1 to active or sham stimulation and receive 12 weekly bilateral sessions of 30 minutes over 12 weeks.
Investigator-initiated academic study sponsored by the General University Hospital in Prague. The primary objective is to determine the effect of peroneal transcutaneous electrical neuromodulation on the frequency of daytime urinary incontinence in children with overactive bladder. The primary variable is the clinical responder rate at the end of treatment (week 12). Secondary objectives are the effect on micturition frequency, functional bladder capacity, parent- and child-reported symptoms and quality of life (DVISS, PIN-Q, PGI-I), clinician-rated global improvement (CGI-I), and the safety, tolerability and adherence to treatment.
Children are randomized 1:1 (permuted blocks, sealed opaque envelopes) to active stimulation or sham stimulation with the stimulation voltage set to 0 V. Both procedures are identical in preparation, electrode placement, duration and the 4 Hz acoustic signal; the child and the parent are separated from the lower limbs by an opaque screen. Planned sample size: 21 evaluable participants per arm; 47 participants are to be enrolled to allow for approximately 10% attrition.
The URIS I device is supplied by the manufacturer, Stimvia s.r.o., under a loan agreement. The manufacturer is not a sponsor or collaborator of this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active bilateral peroneal transcutaneous neuromodulation with URIS I, 30 minutes, once a week for 12 weeks.
Device: Active peroneal transcutaneous neuromodulation (URIS I, Stimvia)
Sham stimulation with URIS I at 0 V (no stimulation delivered), same procedure, electrode placement, 4 Hz acoustic signal and schedule as the active arm: 30 minutes, once a week for 12 weeks.
Device: Sham peroneal transcutaneous neuromodulation (URIS I, Stimvia)
Bilateral peroneal transcutaneous electrical neuromodulation with the URIS I system. A neutral self-adhesive electrode is placed on the lower abdomen; the optimal stimulation point at the lateral edge of the popliteal fossa is identified by a rhythmic motor response of the leg, and the stimulation voltage is set to the lowest value that evokes this response. Stimulation lasts 30 minutes, once a week for 12 weeks (12 sessions). The device emits a 4 Hz acoustic signal.
Identical preparation, electrode placement and duration as active stimulation, but the stimulation voltage is set to 0 V bilaterally so that no stimulation is delivered. Exposure to active stimulation is limited to the minimum needed to locate the stimulation point. 30 minutes, once a week for 12 weeks (12 sessions). The device emits the same 4 Hz acoustic signal.
Proportion of clinical responders at the end of treatment
A clinical responder is a child who meets either or both of the following criteria at the end of treatment: 1. a reduction of at least 50% in the number of wet days during waking hours over 14 days of the wetting diary compared with baseline; 2. a PGI-I score of 2 or less rated by both the parent and the child. PGI-I (Patient Global Impression of Improvement) ranges from 1 = very much better to 7 = very much worse.
Time frame: Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)
Change in the number of daytime incontinence episodes per 24 hours
Number of incontinence episodes during waking hours per 24 hours, averaged over 14 days of the wetting diary; change from baseline.
Time frame: Baseline, Week 6, Week 12
Change in the severity of daytime incontinence episodes
Severity of incontinence episodes (complete vs. partial wetting) per 24 hours during waking hours over 14 days of the wetting diary; change from baseline.
Time frame: Baseline, Week 6, Week 12
Change in the number of wet days
Number of wet days during waking hours over 2 weeks (a wet day is a day with leakage producing a stain on underwear larger than a 10 CZK coin / 1 EUR coin); change from baseline.
Time frame: Baseline, Week 6, Week 12
Change in micturition frequency and functional bladder capacity
Mean number of voids per 24 hours and mean voided volume (functional bladder capacity) from the 48-hour frequency-volume chart; change from baseline.
Time frame: Baseline, Week 6, Week 12
Change in DVISS total score (parent-rated)
Dysfunctional Voiding and Incontinence Symptom Score total score completed by the parent; change from baseline. Higher scores indicate more severe symptoms.
Time frame: Baseline, Week 6, Week 12
Change in Bower PIN-Q total score (child-rated)
Pediatric Incontinence Questionnaire (PIN-Q) total score completed by the child as a measure of quality of life; change from baseline.
Time frame: Baseline, Week 6, Week 12
PGI-I score rated by the child and by the parent
Patient Global Impression of Improvement, rated separately by the child and by the parent (1 = very much better to 7 = very much worse).
Time frame: Week 6, Week 12
CGI-I score rated by the unblinded investigator
Clinical Global Impression of Improvement rated by the principal investigator or co-investigator (1 = very much improved to 7 = very much worse).
Time frame: Week 6, Week 12
Number, type and severity of treatment-related adverse events
Adverse events (description, severity, onset, resolution, action taken and relationship to neuromodulation) recorded at every stimulation session and visit.
Time frame: From the first stimulation to Week 12
Adherence to treatment
Proportion of participants who attend at least 80% of the 12 planned stimulation sessions.
Time frame: Week 12
Plan to share: No — Individual participant data (IPD) will not be shared to protect patient privacy, as this study evaluates a vulnerable pediatric population and is subject to strict GDPR and institutional data protection regulations.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jun 2028, 20 months after the start.
Of 134 non-industry interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 20 months is close to that.
Counting every sponsor, half of 175 studies reached it within 19 months; a quarter within 10 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
General University Hospital, Prague